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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYTo understand how haploinsufficiency of progranulin (PGRN) causes frontotemporal dementia (FTD), we created induced pluripotent
stem cells (iPSCs) from patients carrying the GRNIVS1+5G > C mutation (FTD-iPSCs). FTD-iPSCs were fated to cortical neurons, the cells
most affected in FTD. Although generation of neuroprogenitors was unaffected, their further differentiation into CTIP2-, FOXP2-, or
TBR1-TUJ1 double-positive cortical neurons, but not motorneurons, was significantly decreased in FTD-neural progeny. Zinc finger
nuclease-mediated introduction of GRN cDNA into the AAVS1 locus corrected defects in cortical neurogenesis, demonstrating that
PGRN haploinsufficiency causes inefficient cortical neuron generation. RNA sequencing analysis confirmed reversal of the altered gene
expression profile following genetic correction. We identified the Wnt signaling pathway as one of the top defective pathways in FTD-
iPSC-derived neurons, which was reversed following genetic correction. Differentiation of FTD-iPSCs in the presence of aWNT inhibitor
mitigated defective corticogenesis. Therefore, we demonstrate that PGRN haploinsufficiency hampers corticogenesis in vitro.INTRODUCTION
Frontotemporal dementia (FTD) accounts for 50% of de-
mentia cases before the age of 60. Up to 40% of FTD pa-
tients have a familial history (Goldman et al., 2005; van
Swieten andHeutink, 2008) due tomutations in themicro-
tubule-associated protein tau gene (MAPT), progranulin
gene (GRN), or C9orf72 gene (Baker et al., 2006; Cruts
et al., 2006; DeJesus-Hernandez et al., 2011; Hutton et al.,
1998; Renton et al., 2011). The majority of FTD-causing
mutations in GRN are predicted to result in functional
null alleles, causing haploinsufficiency. Progranulin
(PGRN) has neurotrophic function in vitro and in vivo.
Although PGRN/ mice are viable, they do not recapitu-
late all the features of FTD (Kayasuga et al., 2007).
Human somatic cell reprogramming to a pluripotent
state (induced pluripotent stem cells; iPSCs)(Takahashi
et al., 2007a) can create human disease models in vitro us-
ing patient-derived iPSCs (Kim, 2014), including neurode-generative diseases (Qiang et al., 2013) and, specifically,
FTD (Almeida et al., 2012). Unlike in the published FTD-
iPSC model that differentiated iPSCs to a mixture of
neuronal cells, we evaluated cortical neuron development
from FTD-patient-derived iPSCs, as FTD is characterized
by selective neurodegeneration of the frontal and/or tem-
poral cortex (Neary et al., 2005). We demonstrate that
FTD-iPSCs carrying a GRNIVS1+5G > C mutation differ in
their ability to generate cortical neurons from control lines
(iPSCs and human embryonic stem cells; hESCs) and that
genetic correction restores this differentiation defect.RESULTS
FTD-iPSCs Differentiation into Neuroprogenitors Is
Normal
To study the effect of PGRN haploinsufficiency in human
neurogenesis, iPSC lines were generated from threeStem Cell Reports j Vol. 4 j 1–9 j January 13, 2015 j ª2015 The Authors 1
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(Figure S1A available online) as previously described (Taka-
hashi et al., 2007b). The human embryonic stem cell line,
H9 (H9-ESC), and iPSCs from normal donor fibroblasts
(CTRL-iPSCs) were used as control lines (Figures S1B–
S1E). Transcript and protein levels of PGRN in FTD-iPSC
lines were reduced, approximately 30% and 50%, respec-
tively, compared to H9-hESCs and CTRL-iPSCs (Figures
S1F and S1G). We next induced cortical differentiation
(Espuny-Camacho et al., 2013), which induced an increase
in transcripts for the neuroprogenitor genes SOX1, PAX6,
and FABP7 (BLBP), with concomitant decrease in OCT4
expression in day (d)24 FTD-iPSCs as well as CTRL-iPSC
and H9-hESC progeny (Figure S2A). Immunostaining
confirmed that d24 neuroprogenitors did not express
OCT4. Nearly 100%of the progeny of all lineswere positive
for the neuroectoderm-specific NESTIN marker, with a
PAX6-positive dorsal fate, and stained positive for BLBP
and OTX1-2 (Figure S2B). Thus, neuroprogenitor forma-
tion from FTD-iPSCs appeared normal.
Inefficient Cortical Neuron Formation fromFTD-iPSCs
We next allowed the neuroprogenitors to mature into
cortical neurons. GRN mRNA levels in FTD cells during
differentiation were approximately 50% compared to
control lines (Figure 1A). D40 progeny from CTRL- and
FTD-iPSCs contained functional neurons based on whole-
cell current-clamp analysis. FTD-iPSC neurons consistently
fired action potentials in response to depolarizing current
injections, similar to neurons from control cell lines (Fig-
ures S2CI–S2CII). Whole-cell voltage-clamp recordings
revealed time- and voltage-dependent currents during
depolarizing voltage steps, consistent with functional
voltage-gated Na+ and K+ channels (Figure S2CIII). The
cortical neurotransmitter GABA induced transmembrane
currents in FTD-iPSC-derived neurons, exhibiting the
typical features of ionotropic GABAA receptors (Fig-
ure S2CIV).We also observed spontaneous action potential
firing in FTD-iPSC neurons (Figure S2CV). Thus, FTD-iPSC
neuroprogenitors were able to differentiate into functional,
excitable neurons.
Between d24 and d40 of differentiation, transcript levels
of REELIN, CTIP2, FOXG1, FOXP2, and TBR1 progressively
increased in neural progeny from FTD- and CTRL-iPSC
lines. However, on d40, CTIP2 and FOXG1 mRNA levels
were significantly lower in FTD-iPSC than in CTRL-iPSC
progeny (Figures 1B and S2D). Also, mature TUJ1-positive
neurons coexpressed the cortical markers TBR1, FOXP2,
and CTIP2. However, compared to CTRL-iPSC and H9-
hESC progeny, only a small fraction of FTD-iPSC progeny
was positive for TUJ1 (CTRL-iPSCs, 20.7% ± 3.1%;
FTD-iPSCs, 4.0% ± 0.69%) (Figures 1C and 1D). In both
CTRL-iPSC and FTD-iPSC progeny, a proportion of undif-2 Stem Cell Reports j Vol. 4 j 1–9 j January 13, 2015 j ª2015 The Authorsferentiated NESTIN-positive neuroprogenitors persisted
till d40 (Figure 1E). Thus, using a cortical neuron differen-
tiation protocol, we demonstrate significantly decreased
corticogenesis from FTD-iPSCs.
To test if the neurogenesis defect was specific for cortical
neuron generation, FTD-iPSCs and hESCs were differenti-
ated to motor neurons (Hu and Zhang, 2009). Immuno-
staining for the mature motor neuron markers HB9 and
ISLET1 (Figure 1F) demonstrated that FTD3-iPSCs gener-
ated motor neurons in vitro. Thus, in contrast to what we
observed during cortical neuron differentiation, motor
neuron generation from FTD-iPSCs was not affected.
We stained cortical neuron progeny for activated cas-
pase-3 but found no significant differences in the number
of apoptotic cells between FTD andCTRL lines (Figure S2E).
AsGRNmutations in humans lead to accumulation of TDP-
43-positive inclusions, we performed TDP-43 staining,
which did not identify TDP-43 aggregates, and TDP-43 dis-
played a nuclear staining in all cells (Figure S2F).
Genetic Correction of FTD-iPSCs Restores PGRN Levels
To study the relationship between PGRN haploinsuffi-
ciency and the phenotype observed, we introduced GRN
cDNA by homologous recombination with zinc finger
nucleases (ZFNs) in the AAVS1 locus of FTD3#6-iPSCs
(Figure 2A). To identify correct targeting and absence of
random integrations, we performed genotyping based on
PCR and Southern blot analysis (Figures 2B and 2C). One
correctly homozygously targeted clone (#9) derived from
the FTD3#6 line (hereinafter referred to as FTD3#6-PGRN)
was chosen for complete characterization. As an additional
control, we recombined the GRN cDNA into the AAVS1
locus of H9-hESCs (H9-hESC-PGRN) (Figure S3A).
GRN transcript levels in FTD3#6-PGRN and H9-hESC-
PGRN cells were not significantly different from that in
H9-hESCs (Figure 2D). FTD3#6-PGRN cells expressed the
pluripotency markers at levels comparable to that of H9-
hESCs (Figures 2E and 2F) and formed teratomas (Fig-
ure 2G). Genome integrity of FTD3#6-PGRN, assessed by
array comparative genomic hybridization, revealed no sig-
nificant acquired genetic abnormalities after gene editing,
compared to the original line.
Genetic Correction of FTD-iPSCs Restores Cortical
Neuron Formation
We differentiated FTD3#6-iPSC, FTD3#6-PGRN, H9-hESC,
and H9-hESC-PGRN lines to cortical neurons. Patch clamp
recording confirmed the functional maturity of FTD3#6-
PGRN and H9-hESC-PGRN neurons (data not shown). Dif-
ferentiation toward neuroprogenitors until d24 was similar
for the FTD3#6, FTD3#6-PGRN, H9-ESC, and H9-PGRN
lines, as shown by immunostaining for neuroprogenitor
markers (Figure S3B) and quantitative RT-PCR (Figure S3C).
Figure 1. Generation of Cortical Neurons from FTD-iPSCs and CTRL Lines
(A) GRN levels in FTD-iPSC lines compared to those in control CTRL-iPSC lines (n = 3 independent experiments). Error bars indicate mean ±
SEM. *p < 0.05, t test.
(B) CTIP and FOXG1 expression in d40 progeny of FTD-iPSC and CTRL lines (n = 3 independent experiments). Error bars indicate mean ± SEM.
*p < 0.05, t test.
(C) Immunostaining for TUJ1 and the cortical markers TBR1, CTIP2, and FOXP2. FTD1#1-iPSC and CTRL-iPSC progeny at d40 are shown. Scale
bar, 100 mm.
(D) Enumeration of TUJ1-positive cells in FTD-iPSC and CTRL-iPSC d40 progeny. FTD1#1 and FTD3#6 (FTD) lines and CTRL-iPSC and H9-hESC
(CTRL) lines are shown (n = 3 independent experiments per line. Error bars indicate mean ± SEM. *p < 0.05, t test.
(E) Immunostaining on d40 progeny for Nestin (n = 3). Scale bar, 100 mm.
(F) Immunostaining of FTD3#6 on d40 of differentiation to motorneurons for TUJ1, SMI32, HB9, and ISLET1 (n = 2). Scale bar, 100 mm.
See also Figures S1 and S2.
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progeny expressed significantly higher BLBP, FOXG1, and
CTIP2 transcript levels, which were similar to those in
H9-hESC and H9-hESC-PGRN progeny (Figure 3A; Fig-
ure S3C). Immunostaining for TUJ1 and the cortical
neuron markers CTIP2, FOXP2, and TBR1 demonstrated
that more double-positive cells were present in progenyfrom the FTD3#6-PGRN line compared to the original
isogenic line FTD3#6 (Figure 3B). Quantification of the
number of TUJ1+ and CTIP2+ neurons demonstrated that
FTD3#6-PGRN iPSC progeny contained significantly
more TUJ1+ and CTIP2+ neurons compared with FTD3#6
and that genetic correction partially rescued the fre-
quency of neurons generated compared to CTRL-iPSCsStem Cell Reports j Vol. 4 j 1–9 j January 13, 2015 j ª2015 The Authors 3
Figure 2. Gene Targeting Using ZFNs
(A) Schematic representation of GRN gene targeting in the AAVS1 locus. HA, homology arm; CAGGS, chicken b-actin promoter; HYGR,
hygromycin resistance-thymidine kinase fusion gene. Blue arrows, primers designed for junction assay (JA) PCR at the 50 of the construct;
red arrows, PCR for JA at the 30. PUROR, puromycin resistance.
(B) JA-PCR for several clones; the clone number 9 was selected. +, positive control for 30 JA (engineered H9-hESC line created by L.O.
[unpublished data]); , negative control (FTD-iPSC not targeted).
(C) Southern blot of FTD3#6 and FTD3#6-PGRN lines.
(D) GRN expression in FTD3#6, H9-hESC, FTD3#6-PGRN, and H9-PGRN lines (NS, not significant, p = 1.6, t test; n = 3 different passages).
Error bars indicate mean ± SEM. #p = 0.07; *p < 0.05, t test.
(E) NANOG, OCT4, and DPPA4 expression in FTD3#6, FTD3#6-PGRN, and H9-hESC lines (NS, not significant, p = 0.26, t test; n = 3 different
passages). Error bars indicate mean ± SEM.
(F) Immunostaining of FTD3#6-PGRN for OCT4, SSEA4, and TRA1-60 (n = 3). Scale bar, 100 mm.
(G) FTD3#6-PGRN-derived teratoma with presence of derivatives of all three germ layers. Scale bar, 500 mm.
See also Figure S3.
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1.4%, and FTD3#6, 3.2 %± 0.3%; CTIP2: CTRL-iPSC,
14.2% ± 2.2%, FTD3#6-PGRN 6.2, ± 1.9%, and FTD3#6,
1.6% ± 0.5%) (Figure 3C). Hence, incorporation of GRN
cDNA in the AAVS1 locus restored the ability of FTD-iPSCs
to differentiate to functional neurons with a cortical fate.
As the presence of an extra copy of GRN in H9-hESCs did
not affect the differentiation potential of H9-hESCs, our
studies indicate that deficiency of PGRN is the cause of
the in vitro impaired cortical neuron generation from4 Stem Cell Reports j Vol. 4 j 1–9 j January 13, 2015 j ª2015 The AuthorsFTD-iPSCs. Incorporation ofGRN cDNA in the AAVS1 locus
of FTD3#6 iPSCs did not affect motor neuron differentia-
tion (Figures 3D and 3E).
Genome-wide Transcriptome Analysis of d40
Neuronal Progeny Identifies Increased Wnt Signaling
To gain insights in possible mechanisms underlying the
inefficient cortical neuron generation from FTD-iPSCs, we
performed RNA sequencing (RNA-seq) of d40 progeny
from FTD3#6, FTD3#6-PGRN, and H9-hESC lines. We
Figure 3. Rescue of Corticogenesis in FTD3#6-PGRN Cells
(A) BLBP, FOXG1, and CTIP2 expression in FTD3#6-PGRN, FTD3#6-iPSC, H9-hESC, and H9-PGRN lines (n = 3 independent experiments).
NS, not significant; p = 0.28, p = 0.23, p = 0.2 for top, middle, and bottom panels, respectively, t test. Error bars indicate mean ± SEM.
*p < 0.05, t test.
(B) Immunostaining of FTD3#6 and FTD3#6-PGRN for TUJ1 and CTIP2, FOXP2, and TBR1 (n = 3). Scale bars, 100 mm.
(C) Enumeration of TUJ1-positive (I) and CTIP2-positive cells (II) in d40 progeny from FTD3#6-PGRN iPSCs compared to FTD3#6 and CTRL-
iPSC lines (n = 3 independent experiments per line). Error bars indicate mean ± SEM. *p < 0.05, t test.
(D) Immunostaining of FTD3#6-PGRN for TUJ1 and HB9 (n = 2). Scale bar, 100 mm.
(E) Transcript levels of motorneuron precursor and mature markers (n = 2 independent experiments). Error bars indicate mean ± SEM.
See also Figure S3.
Stem Cell Reports
PGRN Deficiency Induces Impaired Corticogenesisidentified 2,295 genes differentially expressed between d40
progeny of FTD3#6 and H9-hESCs, whereas only 122 genes
were differentially expressed between the FTD3#6-PGRN
and the H9-hESC progeny (Figure 4A).
RNA-seq data corroborated our observation that cortical
neuronal differentiation from FTD-iPSCs is inefficient, as
here too, TUBB3, CTIP2, FOXG1, BLBP, and MAP2 were
significantly downregulated in FTD3#6, compared to H9-
hESCprogeny, and restored in FTD3#6-PGRNprogeny (Fig-
ure 4B). Although we did not see an increase in apoptotic
cells, the RNA-seq data demonstrated that, in line with
the findings in the Almeida et al. (2012) paper, some com-ponents of the MAPK pathway were differentially ex-
pressed in the d40 progeny of FTD3#6 cells compared
with FTD3#6-PGRN and H9-hESC progeny (Figure S4A).
Gene ontology analysis using DAVID demonstrated
that ‘‘neurogenesis,’’ ‘‘generation of neurons,’’ ‘‘neuron
development,’’ ‘‘neuron projection development,’’ and
‘‘synaptic transmission’’ were within the top ‘‘Biological
Processes’’ categories significantly enriched in FTD3#6
versus H9-hESC progeny and in FTD3#6-PGRN versus
FTD3#6 progeny. Ingenuity pathway analysis identified
Wnt/b-catenin signaling as one of the top altered path-
ways. Among other genes, WNT2, WNT3a, WNT5a,Stem Cell Reports j Vol. 4 j 1–9 j January 13, 2015 j ª2015 The Authors 5
Figure 4. Genome-wide Transcriptome Analysis of d40 Neuronal Progeny
(A) Table with the significantly differentially expressed genes (using Benjamini-Hochberg-corrected p values).
(B) Represents the log fold change of gene transcripts of TUBB3, TBR1, FOXP2, CTIP2, FOXG1, BLBP, and MAP2 in d40 neural progeny of the
FTD3#6, H9-hESC, and FTD3#6-PGRN lines from RNA-seq studies.
(C) Wnt signaling pathway, overlaid with the differentially expressed genes (log2 ratio >1 or <1) of FTD3#6 versus H9-hESC line
comparison. Upregulated genes are in green, and downregulated genes are in red.
(D) Western blot for active and total b-catenin on H9-hESCs at d24 treated with DMSO or DMSO-IWP2 (IWP2). b-actin, internal control.
(E) Panel I: Relative expression of BLBP and FOXG1 transcripts in FTD3#6 treated with or without DMSO and IWP2 (n = 3 independent
experiments). Error bars indicate mean ± SEM; *p < 0.05, t test. Panel II: BLBP and FOXG1 transcripts in FTD3#6-iPSC treated with DMSO or
DMSO-IWP2 (IWP2). n = 3 independent experiments. Error bars indicate mean ± SEM. *p < 0.05, t test.
(F) Immunostaining on FTD3#6 d40 progeny treated with DMSO-IWP2 (IWP2) for NESTIN and BLBP or TUJ1 and CTIP2 (n = 3). Scale
bars, 100 mm.
See also Figure S4.
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expressed in FTD3#6 compared to FTD3#6-PGRN and H9-
hESC progeny, whileGSK3b,APC, and PP2Awere expressed
significantly less in FTD3#6-iPSC progeny. However,
expression of genes from the WNT signaling pathway was
similar in FTD3#6-PGRN compared with H9-hESC neural
progeny (Figures 4C and S4B).
To address whether aberrantly activated WNT signaling
was, at least in part, responsible for the defective cortico-6 Stem Cell Reports j Vol. 4 j 1–9 j January 13, 2015 j ª2015 The Authorsgenesis, we induced cortical neuron differentiation of
FTD3#6, FTD3#6-PGRN, and H9-ESC lines in the presence
or absence of the WNT inhibitor, IWP2. Western blot anal-
ysis demonstrated that IWP2 inhibited active b-catenin
levels (Figure 4D). On d40 of differentiation, transcript
levels for BLBP and FOXG1 were significantly higher in
FTD3#6 progeny treated with IWP2, dissolved in DMSO,
compared to FTD3#6 treated with DMSO and untreated
cells (Figures 4E–4I). Of note, addition of DMSO alone
Stem Cell Reports
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progeny, while IWP2 induced a further significant increase
in these transcripts. The increased frequency of neurons in
DMSO-treated FTD-iPSC progeny is possibly an indirect
effect of DMSO-induced PGRN upregulation, as previously
reported (Ong et al., 2006). Consistent with this notion,
addition of DMSO (and IWP2) to differentiation of
FTD3#6-PGRN (Figure 4EII) or H9-hESC (data not shown)
lines did not affect expression of cortical neuron markers.
Immunostaining demonstrated that more BLBP- and
CTIP2-positive cells were generated when IWP2 was added
during the cortical neuron differentiation of FTD3#6 cells
(Figure 4F). Again, this improvement was also visible in
the DMSO-treated cells (data not shown).DISCUSSION
We demonstrate that iPSCs generated from FTD patients
carrying aGRN IVS1+5G > C null mutation poorly differen-
tiate to cortical neurons, while differentiation to motor
neurons appears normal. Introduction of the GRN cDNA
in the AAVS1 locus of FTD-iPSCs using ZFN-mediated ho-
mologous recombination corrected the inefficient cortical
neuron generation. Loss of PGRN caused aberrant activa-
tion of theWNT signaling pathway during neuronal differ-
entiation, and inhibition of WNT signaling partially
rescued the FTD-iPSC corticogenesis defect, further sub-
stantiating the notion that the WNT signaling pathway
might be a therapeutic target for FTD (Korade and Mirnics,
2011).
Almeida et al. (2012) previously demonstrated that
GRNS116X-iPSCs could be differentiated toward neurons
with a similar efficiency as that of control iPSCs but that
GRNS116X-iPSCs were more sensitive to stress. We chose to
differentiate neuronal progenitors from iPSC lines specif-
ically toward the cortical lineage, as we hypothesized that
evaluation of the influence of PGRN haploinsufficiency
on cortical neurons, the most affected cell type in FTD,
would likely yield the most important insights into the
disease. We induced cortical neuron differentiation and
demonstrated that generation of TUJ1-positive cells coex-
pressing cortical markers such as CTIP2, FOXP2, and
TBR1was significantly decreased in FTD-iPSCs. By contrast,
Almeida et al., who differentiated iPSCs sequentially as
embryoid bodies and neurospheres with additional growth
factors to generate a mixture of glutamatergic, GABAergic,
and dopaminergic neurons, did not observe decreased cell
differentiation. We hypothesize that the differences in the
efficiency of neural progeny generation between the two
studies might be caused by the specific subtype of neuronal
cells we generated. In fact, generation of HB9/TUJ1- and
ISLET-1/SMI32-positive motor neurons appeared similarwhen FTD-iPSC or H9-hESC lines were differentiated to
motor neurons.
The role of PGRN in cortical neurons is currently not well
understood. PGRN exerts neurotrophic properties through
a yet-unidentified receptor (De Muynck et al., 2013; Gass
et al., 2012; Van Damme et al., 2008). However, a strong
link between PGRN and the WNT signaling pathway in
neuronal physiology has been established. Rosen et al.
(2011), demonstrated thatGRN knockdown in primary hu-
man neurons activated the canonical and noncanonical
WNT signaling pathway. They also found similar WNT
signaling activation in transcriptome studies of human
GRN mutant brain. Furthermore, knockdown of GRN in a
neural progenitor cell line was shown to inhibit the level
of phosphorylated GSK3b, resulting in canonical WNT
signaling activation and hampered retinoic-acid-mediated
neural differentiation in human cells (Gao et al., 2010).
WNT signaling is also important for pre- and postnatal
neuronal development. WNTsignaling inhibits neuroecto-
derm and forebrain specification (Ming and Song, 2011).
Postnatally, WNT regulates proliferation and maturation
of neural progenitors in the hippocampus and dentate
gyrus (Miranda et al., 2012; Wexler et al., 2009). These
studies identify a very important role of WNT signaling
during brain development, as well as neurogenesis and
neural maturation postnatally.
Transcriptome studies on cortical neuron progeny from
FTD-iPSCs and isogenic genetically corrected FTD-iPSC
and CTRL lines revealed that WNT signaling was among
the top canonical signaling pathways deregulated by GRN
haploinsufficiency. This may explain the decrease in
mature cortical neurons generated, as WNT signaling was
shown to affect proliferation and maturation of cortical
neuronal progenitors (Wexler et al., 2009). However, we
could not identify aberrant activation of the WNT
signaling pathway in the Almeida et al. (2012) transcrip-
tome studies (Figure S4C), which may, again, be due to
differences in neurons generated.
We also demonstrated that aberrant WNT signaling is, at
least partly, responsible for the defective in vitro cortico-
genesis, based on differentiations wherein we added the
WNT inhibitor IWP2, which inhibits WNT processing
and secretion. WNT signaling abnormalities, observed in
our study, are also seen in brains of 6-week-old Grn/
mice (Rosen et al., 2011) before the occurrence of neuroin-
flammation or neuronal apoptosis, suggesting that
aberrant WNT signaling may be an early event in FTD
development. Future studies to assess whether sponta-
neous apoptosis occurs in FTD-iPSC neurons maintained
for longer periods of time, and whether this can be linked
to aberrant WNT signaling, will be of interest.
We found that in vitro corticogenesis is decreased in
GRNIVS1+5G > C-iPSCs; however, brain development inStem Cell Reports j Vol. 4 j 1–9 j January 13, 2015 j ª2015 The Authors 7
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PGRN Deficiency Induces Impaired CorticogenesisGrn+/ and Grn/ mice and in PGRN haploinsufficient pa-
tients appears normal. The reason for the discrepancies
in vitro and in vivo might be that excess of WNT signaling
during early steps of development can be compensated by
other morphogens or cellular interactions, not present in
the culture system. However, it is interesting that in pa-
tients with FTD, evidence of presymptomatic changes ex-
ists (Li et al., 2007).
Neurodegenerative diseases were thought to not be
readily recreated in vitro, as they are late-onset diseases.
However, several papers have shown that disease pheno-
types recapitulated to some extent, using iPSCs (Qiang
et al., 2013). This suggests that cellular and molecular
causes of these diseases of aging may often already be pre-
sent earlier during life and that additional events ulti-
mately lead to the full manifestation of the symptoms of
the disease. In addition, published studies, as well as the
study presented here, suggest that signaling events
required for neurodevelopment may also play major roles
in neurodegeneration and that targeting such pathways—
as for instance, the WNT pathway presented in this
study—may result in the creation of novel therapeutic
approaches for FTD.EXPERIMENTAL PROCEDURES
Primary human fibroblast cultures were obtained from skin bi-
opsies of FTD patients after informed consent; control iPSCs
were generated from BJ fibroblasts. Human iPSC lines were gener-
ated and characterized as previously described (Takahashi et al.,
2007b). hESC and iPSC lines were differentiated toward cortical
or motor neuron progeny as previously described (Espuny-Cama-
cho et al., 2013; Hu and Zhang, 2009). Gene targeting was per-
formed by use of ZFN technology in the AAVS1 locus of iPSCs.
For further information, see the Supplemental Experimental
Procedures.
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SUPPLEMENTAL FIGURES AND LEGENDS 
 
Figure S1, related to Figure1. iPSC generation from FTD patients and 
unaffected control 
(A) DNA sequencing of the GRNIVS1+5G>C mutation in FTD-fibroblasts before 
reprogramming.  
(B) Endogenous SOX2, FGF4, OCT4, NANOG, DPPA4 and REX1 transcripts levels 
in FTD1#1, FTD2#5, and FTD3#6 and CTRL-iPSCs cells compared to H9-hESCs 
(N=3 different passages. N=3 technical replicates of FTD3#6 and FTD2#5 for REX1.  
Error bars indicate mean ± SEM. t test analysis shows no significant differences) 
(C) OCT4, SOX2, KLF4 and C-MYC transgene expression in all the lines compared to 
the d5-transduced fibroblasts. 
(D) Immunostaining for the pluripotency markers TRA-1-60, SSEA4 and OCT4 in H9-
hESCs, FTD-iPSCs and CTRL-iPSCs. FTD1#1 is shown. (N=3 Scale bar = 100µm).  
(E) Teratomas with presence of derivatives of all three germ-layers generated from 
iPSC lines. FTD1#1 is shown as representative of all the FTD-iPSCs.  
Scale bar=500µm.  
	   2	  
(F) Expression levels of GRN transcripts in FTD-iPSCs compared to CTRL lines. The 
average of the CTRL lines and the average of FTD-iPSC lines are shown. (N=3 
different passages. Error bars indicate mean ± SEM. t test=*p = < 0.05). 
(G) ELISA assay for PGRN protein in FTD-iPSCs compared to CTRL cells. The total 
protein was extracted from cells at three different passages; the average of the CTRL 
lines and the average of FTD-iPSC lines are shown. (N=3 different passages. Error 
bars indicate mean ± SEM. t test: *p = < 0.05). 
  
 
Figure S2, related to Figure1. Differentiation of hESCs and iPSCs toward neural 
committed cells 
(A) Transcript levels for the neuro-progenitor marker genes, BLBP, SOX1, and PAX, 
and the pluripotency gene, OCT4, during differentiation of all cell lines (N=3 
independent experiments. Error bars indicate mean ± SEM.  t test: #= p=0.06).  
(B) Representative immunostaining example of one from the three experiments 
performed on neural-rosettes derived from H9-hESCs, CTRL-iPSCs and FTD-iPSCs 
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on d24 of differentiation. FTD1#1 is shown as a representative of all the FTD-iPSC 
lines. (N=3 Scale bar = 100 µm). 
(C) I: Representative action potentials evoked by depolarizing current injection on 
FTD (N=23) and CTRL-iPSC derived neurons (N=4 and N=5 for CTRL-iPSC-
neurons and H9-neurons, respectively). II: Representative transmembrane currents of 
FTD and Ctrl-iPSC derived neurons evoked by depolarizing voltage steps from -120 
to +160 mV in 20 mV steps. III: Negative (red line) and positive (blue line) peak 
currents at different membrane potentials determined in the time curse indicated on 
panel B.  FTD2#5 iPSC and CTRL-iPSC progeny are shown. (N=17, 5 and 5 in case 
of FTD-iPSC-neurons, CTRL-iPSC-neurons and H9-neurons, respectively). IV: 
Representative GABA induced transmembrane currents on an FTD-iPSC derived 
neuron recorder at -70 and 0 mV membrane potential (N=9 of 14 cells tested). V: 
Spontaneous firing detected on an FTD-iPSC derived neuron at d40.  
D) Expression levels of REELIN, TBR1 and FOXP2 of FTD-iPSC compared to 
CTRL-iPSC and H9-hESC lines at d40 of differentiation. (N=3 independent 
experiments. Error bars indicate mean ± SEM. t test analysis shows no significant 
differences)  
(E) Immunostaining for Caspase3 on d40 progeny. FTD3#6 is shown. (Scale 
bar=100µm) 
(F) Immunostaining for TDP43 on d40 progeny. FTD3#6 is shown. (Scale bar=100µ) 
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Figure S3, related to Figure2 and Figure3. Characterization of differentiation 
from FTD3#6, FTD3#6-PGRN, H9-hESC and H9-PGRN lines 
(A) I: Schematic representation of RCME-H9-hESC AAVS1 locus, containing a 
cassette with CAGGS=chicken ß-Actin promoter, GFP=Green Fluorescent protein 
and HYGR/TK=HygromycinR-thymidine kinase fusion gene flanked by FRT 
sequences (violet triangles). II: The gene-targeting vector containing the cDNA of 
PGRN, flanked by FRT sequences (same as in Figure 2A), which allow FLPe-
recombinase mediated cassette exchange. III: The final recombined gene locus after 
integration of the cassette.  
(B) Representative immunostaining example of one from the three experiments 
performed on neural-rosettes derived from H9-hESC-PGRN and FTD3#6-PGRN on 
d24 of differentiation. (N=3 Scale bar = 100µm) 
(C) Transcript levels of PAX6, SOX1, FOXP2, EMX2, DLX2, TBR1, TBR2, REELIN 
and NEUROD1 between d0 and d40 of differentiation for FTD3#6, FTD3#6-PGRN, 
H9-hESC and H9-PGRN lines. (N= 3 independent experiments. Error bars indicate 
mean ± SEM. t test analysis shows no significant differences.) 
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Figure S4, related to Figure4. Genome-wide transcriptome analysis of d40 
neuronal progeny 
(A) MAPK signaling pathway, overlaid with the differentially expressed genes (log2-
ratio > 1 or < -1) of each comparison. FTD3#6 vs. H9-hESC, FTD3#6 vs. FTD3#6-
PGRN and FTD3#6-PGRN vs. H9-hESC comparisons are shown. Upregulated genes 
are colored green and down-regulated genes are colored red. 
(B) WNT signaling pathway, overlaid with the differentially expressed genes (log2-
ratio > 1 or < -1) of FTD3#6 vs. FTD3#6-PGRN and FTD3#6-PGRN vs. H9-hESC 
comparisons. Upregulated genes are colored green and down-regulated genes are 
colored red. 
(C) WNT signaling pathway in Almeida’s paper, overlaid with the differentially 
expressed genes (log2-ratio > 1 or < -1). Upregulated genes are colored green and 
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EXTENDED EXPERIMENTAL PROCEDURES 
 
iPSC generation  
To obtain primary human dermal fibroblast cultures, skin biopsies of FTD patients 
carrying the GRNIVS1+5G>C mutation were obtained after informed consent; control 
iPSC were generated from BJ fibroblasts (Takahashi et al., 2007a). Skin biopsies were 
dissected into small pieces and derived fibroblast cultures were maintained in 
Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM:F-12) 
supplemented with 10% fetal bovine serum (Greiner Bio-One), 0.016% sodium 
bicarbonate (Sigma-Aldrich), 1X MEM non-essential amino acids, 50 U/ml penicillin 
and 50µg/ml streptomycin. Human iPSC lines were generated and characterized as 
previously described using the four Yamanaka transcription factors (TFs) OCT4, 
SOX2, KLF4 and C-MYC (Takahashi et al., 2007b). To exclude contamination, iPSC 
line identity was examined by SNP analysis. Mutation status was confirmed with a 
custom GRNIVS1+5G>C TaqMan SNP genotyping 2 assay and Sanger sequencing. 
 
Teratoma formation and analysis 
FTD-iPSCs, the CTRL-iPSCs and the genetically corrected FTD-iPSC were collected 
through enzymatic dissociation, 5-10 million cells were resuspended in 100µl PBS 
and injected with 100µl matrigel (Becton Dickinson, 354230) subcutaneously in the 
back of severe combined immunodeficient RAG2-/- γc-/- mice. These experiments 
were approved by the Institutional Ethics Committee.  
Tumors generally developed within 4–8 weeks. Animals were sacrificed for 
dissection, teratomas were fixed in 4% paraformaldehyde (overnight), washed in 70% 
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Ethanol and subsequently embedded in paraffin. After sectioning, the presence of 
cells from three germlayers was assessed following hematoxylin and eosin staining. 	  
Array Comparative Genomic Hybridization (aCGH)  
Genomic DNA isolated from the three FDT-iPSC lines as well as the genetically 
using QiaAmp DNA mini kit (Qiagen) were subjected for CNV analysis on 180k 
Cytosure ISCA v2 arrays (Oxford Gene Technology, Oxford, UK).  
 
Southern blot 
Southern blot was performed to determine if random integrations occurred in the 
genome of FTD3#6-PGRN after FTD3#6 gene editing. Genomic DNA (5-7 µg) was 
digested overnight with ECORI and AVRII. The probe was designed on the homology 
arm 1 (HA1) so that also the FTD3#6 will be positive but the fragment would have a 
different size (4 Kb) than the FTD3#6-PGRN (4,7 Kb) for AVRII digested samples. 
  
Differentiation of pluripotent stem cells to cortical neurons 
hESC and iPSC lines were differentiated toward neural-specific progeny into 5 cm 
dishes (150288, NUNC) pre-coated with Matrigel (734-1440, VWR) diluted in 
DMEM:F-12 for 1 h at 37 °C, in a 21% O2 – 5.8% CO2 – 37°C incubator. Cells were 
expanded in mTeSR medium (Stem Cell Technologies, 05850) for two days in 
presence of ROCK inhibitor (Y-27632; 10 µM Millipore, 688001). To induce neural 
differentiation, medium was switched to a Defined Default Medium (DDM) (Gaspard 
et al., 2008) with B27 without Vitamin A (Gibco, 12587-010), supplemented with 
recombinant human Noggin (6057-NG, R&D Systems) for 16 days. All culture media 
and supplements were from Invitrogen unless otherwise stated. 
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The neural progenitor cells on d24 were manually dissociated and transferred on 
laminin/poly-D-Lysine coated glass coverslips and allowed to differentiate without 
medium change until d40.  
In some cultures, 2µM IWP-2 (Stemgent 04-0034), which inactivates PORCN, a 
membrane-bound O-acyltransferase, and selectively inhibits palmitoylation of WNT, 
blocking WNT-dependent phosphorylation of LRP6 receptor and DVL2, and β-
catenin accumulation (Kalani et al., 2008), was added during the differentiation. IWP 
inhibitor is reconstituted in DMSO and therefore the corresponding controls for 
DMSO treatment alone were taken along. 
Quantitative Reverse Transcription PCR 
Total RNA was extracted from human dermal fibroblasts, iPSCs and differentiated 
iPSCs using the RNeasy Mini kit (Qiagen). Total RNA was reverse transcribed to 
cDNA using SuperScript® III reverse transcriptase (Invitrogen). Quantitative PCR 
(qPCR) was done with SYBR Green primers and performed with Platinum SYBR 
green qPCR Supermix-UDG (Invitrogen) with an Eppendorf Realplex (Eppendorf). 
All samples were run in triplicate and relative quantification was done using the ΔΔCt 
method (Pfaffl, 2001) with normalization to GAPDH. Statistical analysis were 
performed using the Student’s t-test, error bars show SEM. A list of primers can be 
found in the Table S3.  
 
Immunocytochemistry 
Immunostaining was performed by fixing the cells with 4% paraformaldehyde for 30 
min or in 10% neutral buffered formalin (NBF) for 15 minutes at room temperature. 
Permeabilization and blocking was done for 30 min using PBS containing 3% BSA 
(Sigma-Aldrich, L9530), 0.3% Triton X-100 (Acros Organics) and 5% donkey serum 
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(Jackson). Cells were then incubated overnight at 4°C with primary antibodies (Abs) 
diluted in PBS with 3% BSA, 1% donkey serum, 0.1% Triton X-100. After three 
washes in PBS, cells were incubated with a mixture of secondary Abs and Hoechst 
(Sigma-Aldrich, 33258) for 90 min at room temperature. Primary Abs and dilutions 
are listed in the Table S4. 
 
Western Blot 
Protein was extracted from d40 cultures. 20µg of total protein was loaded and running 
was performed for 1h at 120 V. PVDF membrane was used for transfer, which was 
carried out for 1h30’ at 100 V. Blocking TBS-T 5% milk was done for 1h at 4°C. 
Primary Ab was kept over night at 4°C and secondary Ab for 1h30’ at RT. 
The WB for total β-catenin WB was performed following stripping the antibody 
against active β-catenin. 
 
Patch-clamp recording 
Whole-cell current-clamp and voltage-clamp measurements were carried out by using 
an EPC-10 amplifier and Patchmaster software (HEKA Elektronik). Pipette electrodes 
were fabricated and fire polished with a final tip resistances 2–5 MΩ. Recordings 
were performed at room temperature in a bath solution containing (in mM): NaCl, 
147; KCl, 2; MgCl2, 2; CaCl2, 1.2; HEPES, 10; glucose, 10 (pH 7.4) and patch 
pipettes were filled with a solution containing (in mM): K-gluconate, 120; KCl, 20; 
NaCl, 10; CaCl2, 1; EGTA, 10; HEPES, 10; Mg-ATP, 4; K-GTP, 0.1 (pH 7.2). In 
voltage clamp measurements, the holding potential was -70 mV, if it is not mentioned 
otherwise. 
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Gene targeting by zinc finger nuclease technology 
Gene targeting was done using a dual vector, containing both the AAVS1 homology 
regions and FRT sequences, suitable for gene targeting and recombinase mediated 
cassette exchange (RMCE)-mediated by Flipase (FLPe) (Ordovas et al., unpublished 
data). A copy of the GRN coding sequence followed by a F2A-GFP-P2A-Hygromycin 
cassette was cloned under the control of the CAGGS promoter into an AAVS1 donor 
plasmid flanked by heterotypic FRT sequences (pZ:F3-P F) (Ordovas et al., 
unpublished data). For gene targeting in FTD-iPSCs, the dual donor plasmid was co-
transfected together with AAVS1-specific ZFN expressing vectors (Mussolino et al., 
2014) in the FTD3#6 cell line as follows:  four million iPSC were nucleofected with 
10µg of gene targeting vector and 3µg of ZFN plasmids using the hESC Nucleofector 
Solution2, and program A23 (Lonza, Walkersville, MD) following the manufacturer’s 
instructions. Cells were plated on inactivated DR4 mouse embryonic fibroblasts 
(GlobalStem, Rockville, MD) in media containing 10µM ROCK inhibitor (Sigma-
Aldrich). Selection with puromycin (Sigma-Aldrich) was applied for up to one week 
starting from 300ng/ml increasing to 700ng/ml. Surviving colonies were individually 
manually selected and then expanded. Genotyping PCRs were performed according to 
standard procedures. 
Generation of H9-hESC-PGRN was achieved by co-transfection of the dual donor 
plasmid and a Flippase expressing vector into an H9-hESCs, previously engineered to 
contain an FRT-flanked cassette into the AAVS1 locus available in our lab. With this 
system, we have shown that after puromycin and 1-(2-deoxy-2-fluoro-beta-D-
arabinofuranosyl)-5-iodouracil (FIAU) positive/negative selection, correct 
recombination in the AAVS1 locus between the FRT sequences without random target 
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integrations is found in 100% of the drug-resistant colonies (Ordovas et al., 
unpublished data).   
RNAseq analysis 
Total RNA was isolated (Sigma) from two biological replicates of the FTD3#6, 
FTD3#6-PGRN and H9-hESC. RNA concentration, quality and integrity was 
determined with spectrophotometry (A260/280, NanoDrop) and the Agilent 
Bioanalyzer. Library preparation was done with the TruSeq Stranded mRNA sample 
prep kit (Illumina) and single-end sequenced with 50bp reads on the HiSeq™2000 
platform (Illumina). Raw reads were subjected to quality control. Average base 
quality per cycle and average read quality was calculated by the ShortRead 1.20.0 
package from Bioconductor (http://www.bioconductor.org). Low quality ends (< 
Q20) were trimmed with FastX 0.0.13. Adapters were trimmed only at the end (at 
least 10 bp overlap and 90% match) with Cutadapt 1.2.1. Reads shorter than 35bp 
after adapter trimming were removed.  
Preprocessed reads were mapped to the reference genome of Homo sapiens 
(GRCh37.73) with Tophat v2.0.8b, and annotated using mergeBed from the Bedtools 
v2.17.0 toolkit. The number of reads in the alignments that overlap with the gene 
features were counted using htseq-count version 2, and merged with the gene 
annotation. Genes with less than 1 count-per-million were removed. Statistical 
comparative analysis to obtain the differentially expressed genes between the 
different sample groups were calculated in Bioconductor. The resulting p-values are 
corrected for multiple testing with Benjamini-Hochberg to control the false discovery 
rate (FDR). 
The data discussed in this publication have been deposited in NCBI's Gene 
Expression Omnibus (Edgar et al., 2002) and are accessible through GEO Series 
accession number GSE60902: 
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 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE60902). 
 
Pathway and gene ontology analysis 
Gene ontology (GO) analysis was performed with the DAVID functional annotation 
tool (for Database for Annotation, Visualisation, and Integrated Discovery) on all 
significant differentially expressed genes between d40 H9-hESC neurons and d40 
FTD3#6 neurons (Benjamini-Hochberg corrected P ≤ 0.05), irrespective of the 
direction of the change (Huang da et al., 2009a, b). The 1979 mapped IDs were 
compared against the Homo Sapiens background for enrichment within the highest-
level (level 5) GO categories biological processes and molecular function. Only GO 
categories with more than three genes were selected. The Expression Analysis 
Systematic Explorer (EASE) score probability, a modified Fisher’s exact test that is 
more conservative in examining P values of gene lists for gene-enrichment analysis, 
was used to calculate P values with a threshold of 0.1. Ingenuity pathway analysis 
(IPA, Ingenuity® Systems) was performed to identify functional pathways and 
molecular networks. The dataset was mapped tot the IPA Knowledge Base and 
mapped IDs (16,170) that met the log ratio cutoff of 0.5 (both up/downregulated) 
were included. Significance values for the overrepresented signaling and metabolic 
pathways are calculated by Fisher's exact right-tailed test. The significance indicates 
the probability of association of molecules from the dataset with the pathway as 










Primary	  Antibodies	   Dilution	   Cat	  Number	  	  
PAX6	   1:2000	   Covance,	  PRB-­‐278P	  
NESTIN	   1:1000	   Covance,	  MMS-­‐570P	  
BLBP	   1:2000	   Chemicon,	  AB9558	  
OTX1-­‐2	   1:2000	   Chemicon,	  AB9566	  
OCT-­‐3/4	   1:2000	   Santa	  Cruz,	  N-­‐19,	  sc-­‐8628	  
SSEA4	   1µg/ml	   Santa	  Cruz,	  sc-­‐21704	  
TRA1-­‐60	   1µg/ml	   Millipore,	  MAB-­‐4360	  
FOXP2	   1:5000	   Abcam,	  ab16046	  
CTIP2	   1:500	   Abcam,	  ab18465	  
TBR1	   1:1000	   Eurogentec	  
Active	  Caspase-­‐3	   1:50	   Millipore	  AB3623	  
TDP-­‐43	   1:1000	   Proteintech	  12892-­‐1-­‐AP	  
ß-­‐Actin	   1:2000	   Biokè	  49705	  
Active	  ß-­‐Catenin	   1:2000	   Upstate	  0566592	  
ßIII-­‐Tubulin	   1:2000	   Covance	  MMS-­‐435P	  
	   	   	  
Isotypes	   Cat	  
Number	  
	  
mouse IgG1  BD Biosciences, 550878 
goat IgG  Jackson, 005-000-002 
rabbit IgG  BD Biosciences, 550875 
	   	   	  
Secondary Antibodies Dilution Cat Number 
D∂Rb Alexa Fluor-
488  
1:500	   Invitrogen,A21206 
D∂Gt Alexa Fluor- 
488 
1:500	   Invitrogen,A11055	  
D∂Ms	  Alexa	  Fluor-­‐488	   1:500	   Invitrogen,A21202	  
D∂Ms	  Alexa	  Fluor-­‐555	   1:500	   Invitrogen,A31570	  
D∂Rb Alexa Fluor-
555  
1:500	   Invitrogen,A31572	  
D∂Gt Alexa Fluor- 
555 
1:500	   Invitrogen,A21432	  








Gene	   Forward	  primer	  	   Reverse	  primer	  
BLBP	   GGACTCTCAGCACATTCAAGAA	   CCACATCACCAAAAGTAAGGGT	  
CTIP2	   G	  A	  G	  T	  A	  C	  T	  G	  C	  G	  G	  C	  A	  A	  G	  G	  T	  G	  T	  T	   T	  A	  G	  T	  T	  G	  C	  A	  C	  A	  G	  C	  T	  C	  G	  C	  A	  C	  T	  T	  
DLX2	   ACGCTCCCTATGGAACCAGTT	   TCCGAATTTCAGGCTCAAGGT	  
EMX2	   GCTTCTAAGGCTGGAACACG	   CCAGCTTCTGCCTTTTGAAC	  
FOXG1	   GCCACAATCTGTCCCTCAACA	   CGGGTCCAGCATCCAGTAG	  
PAX6	   GTGTCTACCAACCAATTCCACAAC	   CCCAACATGGAGCCAGATG	  
REELIN	   G	  T	  A	  G	  C	  A	  A	  G	  C	  C	  C	  T	  T	  C	  A	  G	  C	  A	  A	  C	   C	  C	  C	  T	  G	  A	  G	  G	  C	  C	  A	  G	  T	  A	  C	  A	  A	  C	  A	  T	  
SOX1	   GCAAGATGGCCCAGGAGAA	   CCTCGGACATGACCTTCCA	  
TBR1	   ATGGGCAGATGGTGGTTTTA	   GACGGCGATGAACTGAGTCT	  
GRN	   GTGCCCAGATGGTCAGTTCT	   CCCTGAGACGGTAAAGATGC	  
GAPDH	   GAAGGTGAAGGTCGGAGTC	   GAAGATGGTGATGGGATTTC	  
JA5'	   CACTTTGAGCTCTACTGGCTTC	   CATGTTAGAAGACTTCCTCTGC	  
JA3'	   TTCACTGCATTCTAGTTGTGG	   GGAACGGGGCTCAGTCTG	  
OCT4	   GACAGGGGGAGGGGAGGAGCTAGG	   CTTCCCTCCAACCAGTTGCCCCAAAC	  
DPPA4	   GGAGCCGCCTGCCCTGGAAAATTC	   TTTTCCTGATATTCTATTCCCAT	  
FGF4	   CTACAACGCCTACGAGTCCTACA	   GTTGCACCAGAAAAGTCAGAGTTG	  
NANOG	   CAGCCCCGATTCTTCCACCAGTCCC	   CGGAAGATTCCCAGTCGGGTTCACC	  
REX1	   CAGATCCTAAACAGCTCGCAGAAT	   GCGTACGCAAATTAAAGTCCAGA	  
KLF4	  ex	   ACGATCGTGGCCCCGGAAAAGGACC	   TTATCGTCGACCACTGTGCTGCTG	  
SOX2	  ex	   GGCACCCCTGGCATGGCTCTTGGCTC	   TTATCGTCGACCACTGTGCTGCTG	  
C-­‐MYC	  ex	   CAACAACCGAAAATGCACCAGCCCCAG	   TTATCGTCGACCACTGTGCTGCTG	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